NCT02411448 2026-01-16
RELAY
Eli Lilly and Company
Phase 3 Active not recruiting
Clinical Trials
3 trialsNCT04704934 2026-01-12
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Daiichi Sankyo
Phase 3 Active not recruiting
NCT05633602 2025-05-28
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
SWOG Cancer Research Network
Phase 3 Active not recruiting